华蟾素胶囊联合PC化疗方案治疗晚期非鳞状非小细胞肺癌患者的效果

Effects of Huachansu capsules combined with PC chemotherapy regimen in treatment of patients with advanced non-squamous non-small cell lung cancer

目的:观察华蟾素胶囊联合PC化疗方案治疗晚期非鳞状非小细胞肺癌(NSCLC)患者的效果。方法:选取2016年6月至2019年6月该院收治的94例晚期非鳞状NSCLC患者进行回顾性分析,采用随机数字表法将其分为对照组(n=47)与观察组(n=47)。对照组采用PC化疗方案治疗,研究组在对照组基础上联合华蟾素胶囊治疗,比较两组疾病缓解率、治疗前后T细胞亚群指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平、肿瘤标志物指标[癌胚抗原(CEA)、糖类抗原199(CA199)、细胞角蛋白19片段(CYFRA21-1)、神经特异性烯醇化酶(NSE)]水平、肿瘤相关因子[基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶-14(MMP-14)、血管内皮生长因子(VEGF)]水平,不良反应发生率和生存率。结果:观察组疾病缓解率为82.98%(39/47),高于对照组的61.70%(29/47),差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前,但观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组CEA、CA199、CYFRA21-1、NSE水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组MMP-9、MMP-14、VEGF水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组1、2年生存率均高于对照组,差异有统计学意义(P<0.05)。结论:华蟾素胶囊联合PC化疗方案治疗晚期非鳞状NSCLC患者可提高疾病缓解率、T细胞亚群指标水平和生存率,降低血清肿瘤标志物指标和肿瘤相关因子水平,其效果优于单纯PC化疗方案治疗。

Objective:To observe effects of Huachansu capsules combined with PC chemotherapy regimen in treatment of patients with advanced non-squamous non-small cell lung cancer(NSCLC).Methods:A prospective study was conducted on 94 patients with advanced nonsquamous NSCLC admitted to the hospital from June 2016 to June 2019.They were divided into control group(n=47)and observation group(n=47)by using the random number table method.The control group was treated with PC chemotherapy regimen,while the study group was treated with Huachansu capsules on the basis of that of the control group.The disease remission rate the levels of T cell subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+)),the serum tumor marker levels[carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),cytokeratin 19 fragment(CYFRA21-1),neuronspecific enolase(NSE)],the tumor-related factor levels[serum matrix metalloproteinase-9(MMP-9),matrix metalloproteinase-14(MMP-14),vascular endothelial growth factor(VEGF)],the incidence of adverse reactions and the survival rate were compared between the two groups.Results:The disease remission rate of the observation group was 82.98%(39/47),which was higher than 61.70%(29/47)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were lower than those before the treatment,but those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum CEA,CA199,CYFRA21-1 and NSE in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum MMP-9,MMP-14 and VEGF in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The 1-year and 2-year survival rates of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusions:Huachansu capsules combined with PC chemotherapy regime in the treatment of the patients with advanced non-squamous NSCLC can improve the disease remission rate,the T cell subgroup index levels and the survival rate,and reduce the serum tumor marker index levels and the tumor related factor levels.Moreover,it is superior to single PC chemotherapy regime.